| Literature DB >> 12882912 |
Qing-Sheng Mi1, Dalam Ly, S-E Lamhamedi-Cherradi, Konstantin V Salojin, Li Zhou, Marsha Grattan, Craig Meagher, Peter Zucker, Youhai H Chen, James Nagle, Dennis Taub, Terry L Delovitch.
Abstract
Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is expressed in different tissues and cells, including pancreas and lymphocytes, and can induce apoptosis in various tumor cells but not in most normal cells. The specific roles of TRAIL in health and disease remain unclear. Here we show by cDNA array analyses that TRAIL gene expression is upregulated in pancreatic islets during the development of autoimmune type 1 diabetes in nonobese diabetic (NOD) mice and in Min6 islet beta-cells activated by TNF-alpha + interferon-gamma. However, stimulation of freshly isolated pancreatic islets or Min6 cells with TRAIL did not induce their apoptosis. TRAIL blockade exacerbates the onset of type 1 diabetes in NOD.Scid recipients of transferred diabetogenic T-cells and in cyclophosphamide-treated NOD mice. TRAIL inhibits the proliferation of NOD diabetogenic T-cells by suppressing interleukin (IL)-2 production and cell cycle progression, and this inhibition can be rescued in the presence of exogenous IL-2. cDNA array and Western blot analyses indicate that TRAIL upregulates the expression of the cdk inhibitor p27(kip1). Our data suggest that TRAIL is an important immune regulator of the development of type 1 diabetes.Entities:
Mesh:
Substances:
Year: 2003 PMID: 12882912 DOI: 10.2337/diabetes.52.8.1967
Source DB: PubMed Journal: Diabetes ISSN: 0012-1797 Impact factor: 9.461